Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal centre (GC) B cell differentiation. FL represents ~5% of all haematological neoplasms and ~20–25% of all new non-Hodgkin lymphoma diagnoses in western countries. Tumorigenesis starts in precursor B cells and becomes full-blown tumour when the cells reach the GC maturation step. FL is preceded by an asymptomatic preclinical phase in which premalignant B cells carrying a t(14;18) chromosomal translocation accumulate additional genetic alterations, although not all of these cells progress to the tumour phase. FL is an indolent lymphoma with largely favourable outcomes, although a fraction of patients is at risk of disease progression and adverse outcomes. Outcomes for FL in the rituximab era are encouraging, with ~80% of patients having an overall survival of >10 years. Patients with relapsed FL have a wide range of treatment options, including several chemoimmunotherapy regimens, phosphoinositide 3-kinase inhibitors, and lenalidomide plus rituximab. Promising new treatment approaches include epigenetic therapeutics and immune approaches such as chimeric antigen receptor T cell therapy. The identification of patients at high risk who require alternative therapies to the current standard of care is a growing need that will help direct clinical trial research. This Primer discusses the epidemiology of FL, its molecular and cellular pathogenesis and its diagnosis, classification and treatment.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jaffe, E. S., Swerdlow, S. H. & Vardiman, J. W. in World Cancer Report 2014 (eds Stewart B. W. & Wild C. P.) 482–494 (IARC, 2014).
Jaffe, E., et al. in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed Swerdlow, S. H. et al.) 190–198 (IARC, 2017).
Jaffe, E. S. et al. in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed Swerdlow, S. H. et al.) 266-277 (IARC, 2017).
Hicks, E. B., Rappaport, H. & Winter, W. J. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9, 792–821 (1956).
Lennert, K. & Feller, A. C. in Histopathology of Non-Hodgkin’s Lymphomas 16 (Springer-Verlag, 1992).
Harris, N. L. et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361–1392 (1994).
Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v8–v90 (2016).
Medeiros, L. J. et al. in Tumors of the Lymph Nodes and Spleen. 205–238 (American Registry of Pathology, 2017).
Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J. Clin. Oncol. 33, 2516–2522 (2015).
Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16, 1111–1122 (2015). The study highlights the integration of gene mutations in risk prognostication in FL.
Huet, S. et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 19, 549–561 (2018). This retrospective study evaluates gene expression profiling in outcome prediction in three international cohorts.
Silva, A. et al. Convergence of risk prediction models in follicular lymphoma. Haematologica 104, e25–e255 (2019).
Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443–459 (2016).
Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107, 265–276 (2006).
Smith, A. et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br. J. Cancer 112, 1575–1584 (2015).
NMRN Researchers. Follicular lymphoma. hmrn.org https://www.hmrn.org/statistics/disorders/26 (2019).
Le Guyader-Peyrou, S. et al. Cancer incidence in France over the 1980–2012 period: hematological malignancies. Rev. Epidemiol. Sante Publ. 64, 103–112 (2016).
Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
Agrawal, R. & Wang, J. Pediatric follicular lymphoma: a rare clinicopathologic entity. Arch. Pathol. Lab. Med. 133, 142–146 (2009).
Clarke, C. A. & Glaser, S. L. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94, 2015–2023 (2002).
National Cancer Institute. Cancer stat facts: NHL – follicular lymphoma. cancer.gov https://seer.cancer.gov/statfacts/html/follicular.html (2019).
Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724–3734 (2010).
Clarke, C. A. et al. Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol. Biomark. Prev. 20, 1064–1077 (2011).
Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066–1073 (2014).
Sarkozy, C. et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US Cohorts. J. Clin. Oncol. 37, 144–152 (2019).
Cerhan, J. R. & Slager, S. L. Familial predisposition and genetic risk factors for lymphoma. Blood 126, 2265–2273 (2015).
Linet, M. S. et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 26–40 (2014). A survey from the InterLymph Non-Hodgkin Lymphoma Subtypes Project suggesting that FL has a complex multifactorial aetiology.
Goldin, L. R., Björkholm, M., Kristinsson, S. Y., Turesson, I. & Landgren, O. Highly increased familial risks for specific lymphoma subtypes. Br. J. Haematol. 146, 91–94 (2009).
Skibola, C. F. et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat. Genet. 41, 873–875 (2009).
Wang, S. S. et al. HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes. Cancer Res. 78, 4086–4096 (2018).
Allen, C. D. et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5, 943–952 (2004).
Bonetti, P. et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood 122, 2233–2241 (2013).
Barsotti, A. M. et al. p53-Dependent induction of PVT1 and miR-1204. J. Biol. Chem. 287, 2509–2519 (2012).
Basso, K. & Dalla-Favera, R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv. Immunol. 105, 193–210 (2010).
Skibola, C. F. et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am. J. Hum. Genet. 95, 462–471 (2014).
Morton, L. M. et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 130–144 (2014).
Park, H. Y., Hong, Y., Lee, K. & Koh, J. Vitamin D status and risk of non-Hodgkin lymphoma: an updated meta-analysis. PLOS ONE 14, e0216284 (2019).
Fritschi, L. et al. Occupational exposure to pesticides and risk of non-Hodgkin’s lymphoma. Am. J. Epidemiol. 162, 849–857 (2005).
Koutros, S. et al. Non-Hodgkin lymphoma risk and organophosphate and carbamate insecticide use in the north American pooled project. Env. Int. 127, 199–205 (2019).
Leon, M. E. et al. Pesticide use and risk of non-Hodgkin lymphoid malignancies in agricultural cohorts from France, Norway and the USA: a pooled analysis from the AGRICOH consortium. Int. J. Epidemiol. 48, 1519–1535 (2019).
‘t Mannetje, A. et al. Occupation and risk of Non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Env. Health Perspect. 124, 396–405 (2016).
Chiu, B. C.- et al. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 108, 1363–1369 (2006).
Agopian, J. et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J. Exp. Med. 206, 1473–1483 (2009). The paper describes a molecular connection between agricultural pesticide exposure, clonal expansion of t(14;18)-positive clones and FL risk.
Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. Nat. Rev. Immunol. 15, 172–184 (2015).
Victora, G. D. et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120, 2240–2248 (2012).
Milpied, P., Nadel, B. & Roulland, S. Premalignant cell dynamics in indolent B-cell malignancies. Curr. Opin. Hematol. 22, 388–396 (2015). This paper describes our understanding of the origins and mechanisms of the frequent relapses in FL and chronic lymphocytic leukaemia.
Andor, N. et al. Single-cell RNA-seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. Blood 133, 1119–1129 (2019).
Cleary, M. L. & Sklar, J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl Acad. Sci. USA 82, 7439–7443 (1985).
Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440–1443 (1985).
Liu, Y., Hernandez, A. M., Shibata, D. & Cortopassi, G. A. BCL2 translocation frequency rises with age in humans. Proc. Natl Acad. Sci. USA 91, 8910–8914 (1994).
Roulland, S. et al. BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: lack of seasonal variations in frequency and molecular features. Int. J. Cancer 104, 695–698 (2003).
Schüler, F. et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int. J. Cancer 124, 958–963 (2009).
Roulland, S. et al. Early steps of follicular lymphoma pathogenesis. Adv. Immunol. 111, 1–46 (2011). Occurrence, relevance and dynamics of premalignant cells in the development of FL are described in this paper.
Roulland, S. et al. Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia 20, 158–162 (2006).
Giannelli, F. et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 102, 1196–1201 (2003).
Bell, D. A., Liu, Y. & Cortopassi, G. A. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J. Natl Cancer Inst. 87, 223–224 (1995).
Roulland, S. et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J. Exp. Med. 203, 2425–2431 (2006).
Sungalee, S. et al. Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. J. Clin. Invest. 124, 5337–5351 (2014).
Tellier, J. et al. Human t(14;18)-positive germinal center B cells: a new step in follicular lymphoma pathogenesis? Blood 123, 3462–3465 (2014).
Bende, R. J. et al. Germinal centers in human lymph nodes contain reactivated memory B cells. J. Exp. Med. 204, 2655–2665 (2007).
Dogan, I. et al. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10, 1292–1299 (2009).
McHeyzer-Williams, L. J., Milpied, P. J., Okitsu, S. L. & McHeyzer-Williams, M. G. Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat. Immunol. 16, 296–305 (2015).
Pape, K. A., Taylor, J. J., Maul, R. W., Gearhart, P. J. & Jenkins, M. K. Different B cell populations mediate early and late memory during an endogenous immune response. Science 331, 1203–1207 (2011).
Bretherick, K. L. et al. Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. Blood 116, 6146–6147 (2010).
Roulland, S. et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J. Clin. Oncol. 32, 1347–1355 (2014).
Weigert, O. et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2, 47–55 (2012).
Carlotti, E. et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 113, 3553–3557 (2009).
Araf, S. et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia 32, 1261–1265 (2018).
Kridel, R. et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLOS Med. 13, e1002197 (2016). This paper describes identifying high-risk FL by dynamic monitoring.
Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176–181 (2014). This paper describes many mutations occur early in FL and can be linked by evolution to the cancer precursor cells.
Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep. 6, 130–140 (2014).
Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat Rev. Cancer 14, 517–534 (2014).
Mlynarczyk, C., Fontán, L. & Melnick, A. Germinal center-derived lymphomas: the darkest side of humoral immunity. Immunol. Rev. 288, 214–239 (2019).
Carbone, A., Gloghini, A., Gruss, H. J. & Pinto, A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin’s disease. Am. J. Pathol. 147, 912–922 (1995).
Verdière, L., Mourcin, F. & Tarte, K. Microenvironment signaling driving lymphomagenesis. Curr. Opin. Hematol. 25, 335–345 (2018).
Guilloton, F. et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119, 2556–2567 (2012).
Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8, 22–33 (2008).
Pasqualucci, L. Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol. Rev. 288, 240–261 (2019).
Basso, K. & Dalla-Favera, R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol. Rev. 247, 172–183 (2012).
Graham, J. P., Arcipowski, K. M. & Bishop, G. A. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol. Rev. 237, 226–248 (2010).
Huet, S., Sujobert, P. & Salles, G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat. Rev. Cancer 18, 224–239 (2018).
Pangault, C. et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24, 2080–2089 (2010).
Ame-Thomas, P. et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053–1063 (2012).
Bannard, O. et al. Germinal center centroblasts transition to a centrocyte phenotype according to a timed program and depend on the dark zone for effective selection. Immunity 39, 912–924 (2013).
Pandey, S. et al. IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood 129, 2507–2518 (2017).
Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. & Ansell, S. M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107, 3639–3646 (2006).
Rawal, S. et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J. Immunol. 190, 6681–6693 (2013).
Gregoire, M. et al. Neutrophils trigger a NF-kappaB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget 6, 16471–16487 (2015).
Launay, E. et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 26, 559–562 (2012).
Schmidt, J. et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128, 1101–1111 (2016).
Cheung, K. J. et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 70, 9166–9174 (2010).
Boice, M. et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167, 405–418.e13 (2016).
Mamessier, E. et al. Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites. Haematologica 100, 155 (2015).
Küppers, R. & Stevenson, F. K. Critical influences on the pathogenesis of follicular lymphoma. Blood 131, 2297–2306 (2018).
Amin, R. et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood 126, 1911–1920 (2015).
Linley, A. et al. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood 126, 1902–1910 (2015).
Zhu, D. et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99, 2562–2568 (2002).
Green, M. R. et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA 112, 1116 (2015).
Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).
Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189–195 (2011).
Carlo Visco et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98, 255–263 (2013).
Iqbal, J. et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am. J. Pathol. 165, 159–166 (2004).
Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396–1407 (2018).
Karube, K. et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia 32, 675–684 (2018).
Jardin, F. & Sahota, S. S. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis. Hematology 10, 115–129 (2005).
Bödör, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165–3168 (2013).
Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712–716 (2009).
Honma, K. et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114, 2467–2475 (2009).
Yildiz, M. et al. Activating STAT6 mutations in follicular lymphoma. Blood 125, 668–679 (2015).
Muppidi, J. R. et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 516, 254–258 (2014).
Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
Jiang, Y. et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 7, 38–53 (2017).
Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med. 21, 1199–1208 (2015).
Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med. 21, 1190–1198 (2015).
Zhang, J. et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 7, 322–337 (2017).
Mintz, M. A. et al. The HVEM-BTLA axis restrains T cell help to germinal center B cells and functions as a cell-extrinsic suppressor in lymphomagenesis. Immunity 51, 310–323.e7 (2019).
Ennishi, D. et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9, 546–563 (2019).
Mondello, P. et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. bioRxiv, https://doi.org/10.1101/531954 (2019).
Akasaka, T., Lossos, I. S. & Levy, R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102, 1443–1448 (2003).
Kridel, R. et al. Cell of origin of transformed follicular lymphoma. Blood 126, 2118–2127 (2015).
Bosga-Bouwer, A. G. et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 101, 1149–1154 (2003).
Leich, E. et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 30, 854–860 (2016).
Jardin, F. et al. Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 16, 2309–2317 (2002).
Oricchio, E. et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J. Exp. Med. 211, 1379–1391 (2014).
Correia, C. et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 125, 658–667 (2015).
Zamò, A. et al. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. Leukemia 32, 685–693 (2018).
Gángó, A. et al. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virch. Arch. 473, 453–462 (2018).
Zamò, A. et al. The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Br. J. Haematol. 180, 391–394 (2018).
Martin-Guerrero, I. et al. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica 98, 1237–1241 (2013).
Phelan, J. D. et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature 560, 387–391 (2018).
Dreyling, M. et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 35, 3898–3905 (2017).
Gopal, A. K. et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008–1018 (2014).
Bartlett, N. L. et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131, 182–190 (2018).
Phillips, A. A. & Smith, D. A. Health disparities and the global landscape of lymphoma care today. Am. Soc. Clin. Oncol. Educ. Book 37, 526–534 (2017).
Dada, R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur. J. Haematol. 103, 152–163 (2019).
Choi, S. M., Betz, B. L. & Perry, A. M. Follicular lymphoma diagnostic caveats and updates. Arch. Pathol. Lab. Med. 142, 1330–1340 (2018). This paper highlights diagnostic problems linked to the precise recognition of FL and its correct distinction from other follicle-derived B cell lymphomas.
Sovani, V. et al. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J. Clin. Pathol. 67, 389–395 (2014).
Carbone, A., Gloghini, A., Cabras, A. & Elia, G. The germinal centre-derived lymphomas seen through their cellular microenvironment. Br. J. Haematol. 145, 468–480 (2009).
Karube, K. et al. CD10–MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109, 3076–3079 (2007).
Cong, P. et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 99, 3376–3382 (2002).
Mamessier, E. et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica 99, 481–488 (2014).
Schmidt, J. et al. Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. Leukemia 28, 1103–1112 (2014).
Carbone, A. & Santoro, A. How I treat: diagnosing and managing “in situ” lymphoma. Blood 117, 3954–3960 (2011).
Morita, K. et al. A retrospective study of patients with follicular lymphoma (FL): identification of in situ FL or FL-like B cells of uncertain significance in lymph nodes resected at the time of previous surgery for carcinomas. J. Clin. Pathol. 68, 541–546 (2015).
Fend, F. et al. Early lesions in lymphoid neoplasia: conclusions based on the Workshop of the XV Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden. J. Hematop. 5, 169 (2012).
Carbone, A., Gloghini, A. & Santoro, A. In situ follicular lymphoma: pathologic characteristics and diagnostic features. Hematol. Oncol. 30, 1–7 (2012).
Carbone, A. & Gloghini, A. Emerging issues after the recognition of in situ follicular lymphoma. Leuk. Lymphoma (2013). This review describes pathogenetic data and clinicopathological features of ISFN.
Pruneri, G., Mazzarol, G., Manzotti, M. & Viale, G. Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient. Hum. Pathol. 32, 1410–1413 (2001).
Montes-Moreno, S. et al. Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. Histopathology 56, 658–662 (2010).
Carbone, A. et al. In situ follicular lymphoma associated with nonlymphoid malignancies. Leuk. Lymphoma 53, 603–608 (2012).
Adam, P. et al. Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am. J. Surg. Pathol. 29, 1661–1664 (2005).
Kojima, M. et al. Histological variety of floral variant of follicular lymphoma. APMIS 114, 626–632 (2006).
Osborne, B. M. & Butler, J. J. Follicular lymphoma mimicking progressive transformation of germinal centers. Am. J. Clin. Pathol. 88, 264–269 (1987).
Goates, J. J., Kamel, O. W., LeBrun, D. P., Benharroch, D. & Dorfman, R. F. Floral variant of follicular lymphoma. Immunological and molecular studies support a neoplastic process. Am. J. Surg. Pathol. 18, 37–47 (1994).
Nathwani, B. N. et al. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin’s Lymphoma Classification Project. Hum. Pathol. 30, 263–268 (1999).
Leich, E. et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114, 826–834 (2009).
Skala, S. L., Hristov, B. & Hristov, A. C. Primary cutaneous follicle center lymphoma. Arch Pathol. Lab. Med. 142, 1313–1321 (2018).
Marks, E. & Shi, Y. Duodenal-type follicular lymphoma: a clinicopathologic review. Arch. Pathol. Lab. Med. 142, 542–547 (2018).
Schmidt, J. et al. Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood 130, 323–327 (2017).
Gascoyne, R. D. X. I. V. The pathology of transformation of indolent B cell lymphomas. Hematol. Oncol. 33, 75–79 (2015).
Fischer, T., Zing, N. P. C., Chiattone, C. S., Federico, M. & Luminari, S. Transformed follicular lymphoma. Ann. Hematol. 97, 17–29 (2018).
Medeiros, L. J. et al. in Tumors of the Lymph Nodes and Spleen 79-84 (American Registry of Pathology, 2017).
Solal-Céligny, P. et al. Follicular lymphoma international prognostic index. Blood 104, 1258–1265 (2004).
Buske, C. et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108, 1504–1508 (2006).
Federico, M. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J. Clin. Oncol. 27, 4555–4562 (2009).
Bachy, E. et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132, 49–58 (2018).
Friedberg, J. W. et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J. Clin. Oncol. 27, 1202–1208 (2009).
Wilder, R. B. et al. Long-term results with radiotherapy for stage I–II follicular lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 51, 1219–1227 (2001).
Guadagnolo, B. A. et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 64, 928–934 (2006).
Brady, J. L. et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood 133, 237–245 (2019).
Friedberg, J. W. et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30, 3368–3375 (2012).
Janikova, A. et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk. Lymphoma 56, 2350–2356 (2015).
Seymour, J. F. et al. Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma. J. Clin. Oncol. 21, 2115–2122 (2003).
MacManus, M. et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J. Clin. Oncol. 36, 2918–2925 (2018).
Advani, R., Rosenberg, S. A. & Horning, S. J. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J. Clin. Oncol. 22, 1454–1459 (2004).
Brice, P. et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 15, 1110–1117 (1997).
Ardeshna, K. M. et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362, 516–522 (2003).
Ardeshna, K. M. et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 15, 424–435 (2014).
Hiddemann, W. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106, 3725–3732 (2005).
Herold, M. et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 25, 1986–1992 (2007).
Marcus, R. et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26, 4579–4586 (2008).
Rummel, M. J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381, 1203–1210 (2013).
Flinn, I. W. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123, 2944–2952 (2014).
Flinn, I. W. et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J. Clin. Oncol. 37, 984–991 (2019).
Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42–51 (2011).
Salles, G. A. et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood 130, 486 (2017).
Marcus, R. et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377, 1331–1344 (2017).
Fowler, N. H. et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 15, 1311–1318 (2014).
Martin, P. et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann. Oncol. 28, 2806–2812 (2017).
Morschhauser, F. et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N. Engl. J. Med. 379, 934–947 (2018).
Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059–3068 (2014).
Younes, A. et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol. 28, 1436–1447 (2017).
Scherer, F. et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med. 8, 364ra155 (2016).
Roschewski, M., Staudt, L. M. & Wilson, W. H. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood 127, 3127–3132 (2016).
Al-Tourah, A. J. et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J. Clin. Oncol. 26, 5165–5169 (2008).
Montoto, S. et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 2426–2433 (2007).
Link, B. K. et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J. Clin. Oncol. 31, 3272–3278 (2013).
Maurer, M. J. et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am. J. Hematol. 91, 1096–1101 (2016).
Villa, D. et al. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma. Biol. Blood Marrow Transpl. 20, 1813–1818 (2014).
Kahl, B. S. et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402. J. Clin. Oncol. 32, 3096–3102 (2014).
Martinelli, G. et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J. Clin. Oncol. 28, 4480–4484 (2010).
Ghielmini, M. et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103, 4416–4423 (2004).
Sehn, L. H. et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 17, 1081–1093 (2016).
Cheson, B. D. et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J. Clin. Oncol. 36, 2259–2266 (2018).
Leonard, J. P. et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37, 1188–1199 (2019).
Dreyling, M. et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann. Oncol. 28, 2169–2178 (2017).
Flinn, I. W. et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J. Clin. Oncol. 37, 912–922 (2019).
Leonard, J. P. et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J. Clin. Oncol. 33, 3635–3640 (2015).
Morschhauser, F. et al. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood 132, 1486–1494 (2018).
Italiano, A. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19, 649–659 (2018).
Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013).
[No authors listed.] Positive results for tazemetostat in follicular lymphoma. Cancer Discov. 8, OF3 (2018).
Ribrag, V. et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 102, 903–909 (2017).
Evens, A. M. et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res 22, 1059–1066 (2016).
Kirschbaum, M. et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 1198–1203 (2011).
Chen, R. et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica 100, 357–362 (2015).
Batlevi, C. L. et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br. J. Haematol. 178, 434–441 (2017).
Budde, L. E. et al. Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood 132, 399 (2018).
Morschhauser, F. et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 6, e254–e265 (2019).
Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl. J. Med. 377, 2545–2554 (2017).
Magnano, L. et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br. J. Haematol. 185, 480–491 (2019).
Montoto, S. et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann. Oncol. 13, 523–530 (2002).
Jurinovic, V. et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128, 1112–1120 (2016).
Shi, Q. et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J. Clin. Oncol. 35, 552–560 (2017).
Federico, M. et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 5, e359–e367 (2018). This paper provides outcomes for FL in the rituximab era, and analyses the risk of transformation.
Alonso-Álvarez, S. et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br. J. Haematol. 178, 699–708 (2017).
Giri, S. et al. Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study. Clin. Lymphoma Myeloma Leuk. 17, 569–574 (2017).
Witzens-Harig, M. et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann. Hematol. 93, 1717–1724 (2014).
Hiddemann, W. et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J. Clin. Oncol. 36, 2395–2404 (2018).
Hill, B. T. et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br. J. Haematol. 184, 524–535 (2019).
Coutré, S. E. et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk. Lymphoma 56, 2779–2786 (2015).
Salles, G. et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica 102, e156–e159 (2017).
de Weerdt, I., Koopmans, S. M., Kater, A. P. & van Gelder, M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 102, 1629–1639 (2017).
Dhillon, S. Obinutuzumab: a review in rituximab-refractory or -relapsed follicular lymphoma. Target Oncol. 12, 255–262 (2017).
Radford, J. et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 122, 1137–1143 (2013).
Luminari, S. et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J. Clin. Oncol. 36, 689–696 (2018).
Watanabe, T. et al. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 5, e520–e531 (2018).
Vitolo, U. & Chiappella, A. Histological transformation and secondary malignancies in follicular lymphoma. Lancet Haematol. 5, e496–e497 (2018).
Pettengell, R. et al. The impact of follicular lymphoma on health-related quality of life. Ann. Oncol. 19, 570–576 (2008).
Wagner-Johnston, N. D. et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126, 851–857 (2015).
Yuda, S. et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann. Hematol. 95, 2017–2022 (2016).
Madsen, C. et al. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. Blood Adv. 2, 1562–1571 (2018).
Green, M. R. et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013). The paper describes a genomics approach to FL during evolution and progression.
Horton, S. J. et al. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat. Cell Biol. 19, 1093–1104 (2017).
Zinzani, P. L. et al. Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed/refractory follicular lymphoma: interim data. Blood 128, 617 (2016).
Hinohara, K. & Polyak, K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol. 29, 569–579 (2019).
Milpied, P. et al. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat. Immunol. 19, 1013–1024 (2018).
Cottereau, A. S. et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood 131, 2449–2453 (2018).
Trotman, J. et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 19, 1530–1542 (2018).
Soumerai, J. D. et al. Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). JCO 36, 7519 (2018).
Nastoupil, L. J. et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an open-label, phase II study. JCO 35, 7519 (2017).
Morschhauser, F. et al. Interim report from a phase 2 multicenter study of tazemetostat, an ezh2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol. Oncol. 35, 24–25 (2017).
Gascoyne, J. et al. Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematol. Oncol. 35, 397–407 (2017).
Mourcin, F., Pangault, C., Amin-Ali, R., Amé-Thomas, P. & Tarte, K. Stromal cell contribution to human follicular lymphoma pathogenesis. Front. Immunol. https://doi.org/10.3389/fimmu.2012.00280 (2012).
Rosenberg, S. A. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat. Rep. 61, 1023–1027 (1977).
UICC TNM Classification of Malignant Tumours (eds Brierley, J. D., Gospodarowicz, M. K. & Wittekind, C.) (Wiley Blackwell, 2017).
Migliazza, A. et al. Frequent somatic hypermutation of the 5’ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl Acad. Sci. USA 92, 12520–12524 (1995).
Iqbal, J. et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21, 2332–2343 (2007).
Oricchio, E. et al. Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci. Transl. Med. 9 (2017).
Okosun, J. et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat. Genet. 48, 183–188 (2016).
The authors thank V. Matarese (Centro di Riferimento Oncologico di Aviano) for scientific editing of an early draft of the “Mechanisms/pathophysiology” and “Diagnosis, screening and prevention” sections, and Tables 1 and 2, Box 1 and Fig. 1. A.G. is supported in part by the Italian Ministry of Health (5×1000 Funds–2015), through institutional grant BRI2018 ‘Progetto 6 — visualizing immunomodulatory molecules in individual human cancer cells using in situ bright field multiplexing methods and an innovative proximity detection assay’. S.R. is supported by the Fondation ARC, Cancéropôle Provence-Alpes-Côte d’Azur, the Institut National du Cancer, and by institutional grants from INSERM and CNRS.
A.Y. receives research support from BMS, Curis, Janssen, Merck, Roche and Syndax; honoraria from Abbvie, Curis, Epizyme, Janssen, Merck, Roche and Takeda; and has a consulting role for Biopath, Celgene, Epizyme, HCM, Roche and Xynomics. G.v.K. receives honoraria from Pharmacyclics and has a consulting or advisory role for Bayer, Genentech and Pharmacyclics. A.L.-G. receives research funding from Roche and Gilead and has an advisory role for Bayer, Gilead, Janssen, Novartis, Pfizer (not personal fees) and Roche. J.F. receives research funding from Epizyme and honoraria from Gilead and Roche. All other authors declare no competing interests.
Peer review information
Nature Reviews Disease Primers thanks W. Hiddemann, L. Nastoupil, K. Tarte and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Carbone, A., Roulland, S., Gloghini, A. et al. Follicular lymphoma. Nat Rev Dis Primers 5, 83 (2019). https://doi.org/10.1038/s41572-019-0132-x
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation
The Journal of Pathology: Clinical Research (2021)
Clinical Cancer Research (2021)
Human Pathology (2021)